Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Xenon Pharmaceuticals Announces Proposed Public Offering
Details : The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Product Name : XEN1101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 29, 2023
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
Details : The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Product Name : XEN1101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 29, 2023
Lead Product(s) : XEN1101
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XEN1101 is a differentiated Kv7 potassium channel opener which is being evaluated under phase 2 clinical trials for the treatment of major depressive disorder (MDD).
Product Name : XEN1101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 27, 2023
Lead Product(s) : XEN1101
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Product Name : XEN1101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 12, 2023
Lead Product(s) : NBI-921352
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Neurocrine Biosciences
Deal Size : $1,775.0 million
Deal Type : Collaboration
Details : Xenon has an ongoing collaboration with Neurocrine Biosciences to develop treatments for epilepsy. Neurocrine Biosciences has an exclusive license to XEN901, now known as NBI-921352, a selective Nav1.6 sodium channel inhibitor.
Product Name : NBI-921352
Product Type : Other Small Molecule
Upfront Cash : $50.0 million
December 01, 2022
Lead Product(s) : NBI-921352
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Neurocrine Biosciences
Deal Size : $1,775.0 million
Deal Type : Collaboration
Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program
Details : New XEN1101 Phase 2b X-TOLE sub-group analysis demonstrates statistically significant efficacy results at all doses at Week 1, differentiating XEN1101 with rapid onset to seizure reduction.
Product Name : XEN1101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2022
Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA
Details : The primary efficacy endpoint is the median percent change (MPC) in monthly seizure frequency from baseline through the DBP of XEN1101 compared to placebo.
Product Name : XEN1101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2022
Details : XEN1101 is a differentiated Kv7 potassium channel opener administered as an adjunctive treatment for adult patients with focal epilepsy,being developed for the treatment of epilepsy and major depressive disorder.
Product Name : XEN1101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : XEN1101
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XEN1101, a KCNQ channel opener, has been studied in Phase 2b clinical trial in adult patients demonstrated compelling efficacy results, with a statistically significant and dose-dependent reduction from baseline in monthly focal seizure frequency when co...
Product Name : XEN1101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2022
Lead Product(s) : XEN1101
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Xenon Pharmaceuticals Announces Pricing of $100.0 Million Public Offering
Details : XEN496, a Kv7 potassium channel modulator that is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE).
Product Name : XEN496
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 03, 2021
Reset All
